Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study To the Editor: Although secukinumab emerged as a leader in psoriatic therapy, its loss of efficacy may occur earlier and at higher rates than previously shown in phase III randomized controlled trials (RCTs). 1 The purpose of the present study was to assess the efficacy and safety of secukinumab beyond week 12 and determine whether real-world patients with psoriasis experience long-term outcomes similar to those of individuals enrolled in RCTs.
Following approval by the local research ethics committee, we performed a multicenter retrospective chart review of patients with psoriasis who were 18 years of age or older with a Psoriasis Area and Severity Index (PASI) score of 10 or higher at treatment baseline. All patients received secukinumab 300 mg at time 0, 1, 2, 3, and 4, followed by monthly maintenance dosing thereafter. The clinically significant end point for efficacy was the proportion of subjects who achieved a 75% or greater reduction in PASI from baseline (PASI 75) or Physician Global Assessment (PGA) score of 0 (clear) or 1 (almost clear) when PASI was not documented. Safety was quantified by using reported adverse events (AEs). Patients were treated and followed at 2 academic dermatology clinics in Toronto, Ontario, Canada, and end points were assessed by staff dermatologists at weeks 12 and 52 or at time of treatment discontinuation.
All 41 patients included in our analysis had moderate-to-severe plaque psoriasis, achieved PASI 75 or PGA 0/1 at week 12, and were followed up to week 52 or time of secukinumab discontinuation (Table I) Our results suggest that fewer patients treated with secukinumab maintain a PASI 75 response at week 52 (rate in the present study, 68.3%) than outlined in RCTs (FIXTURE, 84.3%; ERASURE, 80.5%; and SCULPTURE, 78.2%). 2, 3 This may, in part, be due to patient dissatisfaction following minor disease relapse. It appears that a shift in patient expectations to achieve PASI 90 or 100 has become more common, driving higher rates of discontinuation in real-world clinical practice. 4 Despite this, our results, according to which loss of efficacy occurred at 40.0 weeks, do not support previous findings reporting loss of efficacy occurs considerably earlier (according to Huang et al, at 24-32 weeks) than seen with most other biologics (at 44.8 weeks with infliximab, 42.0 weeks with ustekinumab, 33.3 weeks with adalimumab, and 22.4 weeks with etanercept). 1, 5 Similar to RCTs, AEs following 12 weeks of treatment were uncommon (n ¼ 7 [17.1%]). Commonly reported AEs included diarrhea (n ¼ 2 [4.9%]) and respiratory tract infection (nasopharyngitis and bronchitis) (n ¼ 2 [4.9%]). Notably, 1 individual experienced 3 separate episodes (in weeks 21, 35, and 39) of vomiting, diarrhea, fever, abdominal pain, and bloody stool. Similarly, 1 patient experienced irregular episodes of diarrhea throughout the 52-week treatment period. Despite early findings suggesting that secukinumab may elicit or worsen inflammatory bowel disease symptoms, both patients are continuing to receive treatment and responding exceptionally well, with near skin clearance at week 52. Discontinuation because of intolerance was uncommon, with just 1 patient stopping treatment between weeks 12 and 52 because of an episode of nasopharyngitis lasting several weeks.
Overall, our results suggest that fewer patients with psoriasis in real-world clinical practice maintain efficacious outcomes at week 52 than those enrolled in RCTs, with the majority of these patients discontinuing secukinumab treatment around week 40 because of lack of efficacy.
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Effectiveness of low-level laser therapy in lichen planopilaris
To the Editor: Lichen planopilaris (LPP) is a lymphocytic scarring alopecia of unknown origin in which the hair follicle stem cells are destroyed by an autoimmune mechanism. 1, 2 This condition tends to be progressive, and the most effective 
